Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII

Summary

This retrospective survey of haemophilia A patients from multiple treatment centres in Ireland assessed the development of inhibitors following a switch in the prescribed treatment from recombinant factor VIII (rFVIII) produced by Chinese hamster ovary (CHO) cells (rFVIII-CHO) to rFVIII produced by baby hamster kidney (BHK) cells (rFVIII-BHK). Ninety-four patients participated in the survey. Most patients (89.4%) had severe haemophilia. One of 77 (1.3%) patients with no inhibitor history developed an inhibitor. This was a patient with moderate haemophilia A who developed a transient, low-titre (1 BU) de novo inhibitor following surgery. Recurrent inhibitors were detected in three of 17 patients with an inhibitor history during the 20-month post-switch study period. All patients continued on rFVIII-BHK therapy, and all tested negative for inhibitors at the time of their last inhibitor assay during the observation period. These results are consistent with the low levels of inhibitor formation demonstrated in phase III studies of previously treated patients receiving BHK-produced rFVIII and support the low risk of inhibitor formation following a change from rFVIIICHO to rFVIII-BHK.

Keywords

Recombinant factor VIII - FVIII inhibitor - FVIII-CHO - FVIII-BHK

• References

• 1 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-435.
• 2 Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000; 85: 7-13.
• 3 Rosendaal FR, Nieuwenhuis HK, Van den Berg HM. et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180-2186.
• 4 Astermark J, Oldenburg J, Carlson J. et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-3745.
• 5 Astermark J, Oldenburg J, Pavlova A. et al. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-3172.
• 6 Astermark J. Overview of inhibitors. Semin Hematol 2006; 43: S3-S7.
• 7 White GC, DiMichele D, Mertens K. et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 462.
• 8 Peerlinck K, Arnout J, Gilles JG. et al. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-118.
• 9 Peerlinck K, Arnout J, Di Giambattista M. et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-86.
• 10 Sawamoto Y, Prescott R, Zhong D. et al. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factorVIII, CPS-P in previously treated hemophilia A patients without inhibitors. Thromb Haemost 1998; 79: 62-68.
• 11 Keeling D. Switching between full-length and B-domain-deleted factor VIII and the risk of inhibitors. Haemophilia 2006; 12: 690-691.
• 12 Roussel-Robert V, Torchet MF, Legrand F. et al. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. J Thromb Haemost 2003; 1: 2450-2451.
• 13 Scharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia 2001; 7: 346-348.
• 14 Bayer PLC. Kogenate Bayer 250IU, 500IU, & 1000IU (Bio-Set). Specific product characteristics. Available at: http://emc.medicines.org.uk . Accessed January 26, 2007.
• 15 Verbruggen B, Novakova I, Wessels H. et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
• 16 Aventis.. DDAVP Injection [prescribing information]. Bridgewater, NJ:: Aventis;; 2006
• 17 Abshire TC, Brackmann HH, Scharrer I. et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate- FS Study Group. Thromb Haemost 2000; 83: 811-816.
• 18 Giles AR, Rivard GE, Teitel J. et al. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-148.
• 19 Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12 (Suppl. 03) 52-60.
• 20 Santagostino E, Mancuso M, Van der Bom J. et al. Intensity of treatment/prophylaxis and the risk to develop inhibitors among previously untreated patients with severe hemophilia: the CANAL study. Presented at: World Hemophilia Congress; May 21–25, 2006; Vancouver, BC. Abstract 14, PO 386.
• 21 Manuel DC. Intensive exposure to factor VIII may be a risk factor for inhibitor development in mild hemophilia A. Semin Hematol 2006; 43 (01) S89.
• 22 Morado M, Villar A, Jimenez Y. et al. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005; 11: 79-83.
• 23 Santagostino E, Mancuso ME, Rocino A. et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-427.